Amino Acid Metabolism and Tryptophan Pathway
1 Tryptophan Metabolism: NIH Study Findings
The NIH deep phenotyping study documented significant abnormalities in tryptophan metabolism in cerebrospinal fluid (Walitt et al. 2024). Tryptophan is an essential amino acid that serves as precursor for:
- Serotonin: Via tryptophan hydroxylase pathway
- Melatonin: Via serotonin N-acetyltransferase
- Kynurenine pathway metabolites: Via indoleamine 2,3-dioxygenase (IDO)
The Kynurenine Pathway Approximately 95% of dietary tryptophan is metabolized through the kynurenine pathway:
- Tryptophan → Kynurenine: Rate-limiting step; induced by inflammatory cytokines (IFN-\(\gamma\))
- Kynurenine → Kynurenic acid: Neuroprotective branch (NMDA antagonist)
- Kynurenine → 3-hydroxykynurenine → Quinolinic acid: Neurotoxic branch
- Quinolinic acid: NMDA receptor agonist, excitotoxin, pro-oxidant
ME/CFS Kynurenine Pathway Abnormalities
- Increased IDO activity (driven by inflammation)
- Elevated kynurenine/tryptophan ratio
- Increased neurotoxic metabolites (quinolinic acid, 3-HK)
- Reduced neuroprotective metabolites (kynurenic acid) in some studies
- Depletion of tryptophan available for serotonin synthesis
2 Implications for Neurotransmitter Production
Tryptophan diversion into the kynurenine pathway reduces serotonin synthesis:
- Serotonin depletion: May contribute to mood symptoms, pain, sleep disturbance
- Melatonin reduction: May explain sleep-wake cycle disruption
- Quinolinic acid excess: May cause excitotoxicity and cognitive dysfunction
- Oxidative stress: 3-hydroxykynurenine generates free radicals
3 Other Amino Acid Abnormalities
Metabolomic studies have identified broader amino acid disturbances:
- Branched-chain amino acids: Often altered; important for muscle metabolism
- Glutamate/glutamine: Excitatory neurotransmitter precursors
- Glycine: Inhibitory neurotransmitter, glutathione precursor
- Cysteine: Rate-limiting for glutathione synthesis
4 Homocysteine and Methylation Cycle
Elevated homocysteine — whether arising from methylenetetrahydrofolate reductase (MTHFR) polymorphisms, B12 or folate deficiency, or post-viral methylation depletion — may contribute to the mitochondrial dysfunction documented in ME/CFS through direct inhibition of electron transport chain (ETC) complexes.
Mechanistic evidence from cardiovascular and neurological models documents that hyperhomocysteinemia (HHcy) reduces activities of ETC complexes I–V in cardiac and neural tissue, generates reactive oxygen species (ROS) through both direct auto-oxidation and secondary ETC impairment, and depletes mitochondrial antioxidant defenses (superoxide dismutase, catalase) (Kaplan et al. 2020). Additionally, the reactive metabolite homocysteine thiolactone causes N-homocysteinylation of cytochrome c, directly disrupting electron transfer (Kaplan et al. 2020).
Clinically, Regland et al. found that all 12 FM/CFS patients examined showed elevated cerebrospinal fluid (CSF) homocysteine (with normal serum levels), and that CSF homocysteine correlated positively with fatiguability severity . This CNS-compartment-specific elevation suggests that routine serum homocysteine testing may underdetect a metabolically relevant abnormality in a subset of ME/CFS patients.
A separate genetic predisposition pathway involves MTHFR C677T polymorphism, which reduces enzyme activity to 25–67% of normal, impairing remethylation of homocysteine to methionine . Disrupted one-carbon metabolism from MTHFR dysfunction also affects mitochondrial DNA methylation, with downstream consequences for OXPHOS gene expression .
Testable predictions: (1) ME/CFS patients with MTHFR TT genotype should show higher CSF homocysteine than CT or CC genotype patients. (2) CSF homocysteine levels should correlate with ETC complex activity in PBMCs in the same patients. (3) MTHFR-guided B12/folate supplementation should preferentially reduce fatigue in ME/CFS patients with confirmed elevated CSF homocysteine.
Limitations: The ETC inhibition data are from animal and in vitro cardiovascular/neurological models, not from ME/CFS patients. The Regland 1997 CSF study has n=12 and no control group. The proposed MTHFR–HHcy–ETC–fatigue causal chain, while mechanistically coherent, has not been tested as an integrated pathway in ME/CFS.
(Certainty: Low; animal/in vitro mechanism + single small clinical study; not yet independently replicated.)